title: Adjuvant therapy for gastric cancer: what have we learned since INT0116?
abstract: Gastric cancer is one of the main cancer-related causes of death worldwide. The curative treatment of gastric cancer consists of tumor resection and lymphadenectomy. However, surgical treatment alone is associated with high recurrence rates. Adjuvant treatment strategies have been studied over the last decades, but there have been controversial results from the initial studies. The pivotal INT0116 study demonstrated that the use of adjuvant chemoradiotherapy with 5-fluorouracil increases relapse-free and overall survival, and it has been adopted across the Western world. The high toxicity of radiochemotherapy and suboptimal surgical treatment employed, with fewer than 10% of the patients submitted to D2 lymphadenectomy, were the main study limitations. Since its publication, other adjuvant treatment modalities have been studied, and radiochemotherapy is being refined to improve its efficacy and safety. A multimodal approach has been demonstrated to significantly increase relapse-free and overall survival, and it can be offered in the form of perioperative chemotherapy, adjuvant chemoradiotherapy or adjuvant chemotherapy, regardless of the extent of lymphadenectomy. The objective of the present review is to report the major advances obtained in the last decades in the adjuvant treatment of gastric cancer as well as the perspectives of treatment based on recent knowledge of the molecular biology of the disease.
authors: Alexandre A Jácome, Department of Medical Oncology, Hospital Mater Dei, Belo Horizonte 30190-131, Minas Gerais, Brazil.
authors: Alexandre A
authors: AA
authors: Jácome
authors: Alexandre A Jácome, Department of Medical Oncology, Hospital Mater Dei, Belo Horizonte 30190-131, Minas Gerais, Brazil.
authors: Ajith K
authors: AK
authors: Sankarankutty
authors: Alexandre A Jácome, Department of Medical Oncology, Hospital Mater Dei, Belo Horizonte 30190-131, Minas Gerais, Brazil.
authors: José Sebastião
authors: JS
authors: dos Santos
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics; D059186:Chemoradiotherapy, Adjuvant; D017024:Chemotherapy, Adjuvant; D018450:Disease Progression; D018572:Disease-Free Survival; D005743:Gastrectomy / Q000009:adverse effects / Q000401:mortality; D006801:Humans; D008197:Lymph Node Excision; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local; D057285:Precision Medicine; D018714:Radiotherapy, Adjuvant; D012307:Risk Factors; D013274:Stomach Neoplasms / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor
keywords: Adjuvant chemotherapy; Adjuvant radiotherapy; Genes erbB-2; Histology; Stomach neoplasms